Anlon Healthcare

BSE: AHCL · Pharmaceuticals

52W Range₹13 ₹173

Snapshot

Unlock Anlon Healthcare's vital signs

Growth · Profitability · Valuation · Strength · Conviction

Company Overview

Business

Anlon Healthcare Limited is a chemical manufacturing company specialising in the production of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company also provides custom manufacturing services for complex and novel chemical compounds.

Business Model

The company generates revenue through the sale of high-purity chemical intermediates and APIs used in finished dosage formulations, nutraceuticals, and veterinary products. It further monetises its technical capabilities by offering custom manufacturing services for specialised chemical compounds.

Growth Outlook

Growth is driven by the recent expansion into custom manufacturing services for complex chemical compounds. The company continues to leverage its expertise in high-purity chemicals to serve diverse sectors including personal care and pharmaceuticals.

Key Risks

  • Regulatory Compliance. The company is subject to stringent quality and safety regulations governing the pharmaceutical and chemical manufacturing industries.
  • Raw Material Price Volatility. Fluctuations in the cost of chemical raw materials can significantly impact profit margins.
  • Market Competition. The pharmaceutical intermediate and API sector is highly competitive, requiring continuous investment in process innovation.

Price

Start your research today

Unlock AI insights, financials, peers and live data on Anlon Healthcare and 5,000+ companies — free.

Start your research

Peers · Pharmaceuticals

CompanyMkt Cap (Cr)P/EEV/EBITDARev Gr YoYEBITDA MgnROEROCE1Y Return
Anlon HealthcareAHCL
6051.9713.9226.3%13.3%20.9%
Bharat Parenter.BPLPHARMA
68933.0014.739.4%21.2%8.3%9.0%-16.7%
Themis MedicareTHEMISMED
663864.77116.11-15.6%2.8%0.3%-0.3%-9.9%
Shree Ganesh RemSGRL
62447.0522.4034.8%11.9%15.9%+7.6%
KopranKOPRAN
56138.2718.228.2%9.1%4.9%7.7%+12.4%
Influx Health.INFLUX
50820.0%+79.7%

As of Q4 FY26

Financials